ATACANA GROUP Inc.’s Post

💡 Pharma Industry Updates You Should Know 💡 Exciting developments are shaping the pharmaceutical and biotech landscape! Here’s a quick roundup of noteworthy advancements and decisions: 1️⃣ Bristol Myers Squibb – Sotyktu Successful Phase III trials for psoriatic arthritis, delivering significant improvements in joint and skin symptoms. 2️⃣ Novo Nordisk – Alhemo FDA approval for Alhemo (concizumab) to prevent bleeding episodes in hemophilia A or B with inhibitors—transforming care for patients. 3️⃣ Axsome Therapeutics – AXS-05 Positive Phase III results for treating agitation in Alzheimer's disease, marking a breakthrough in addressing this challenging symptom. 4️⃣ Pfizer & Sangamo Therapeutics Pfizer returned rights to Sangamo’s investigational gene therapy for hemophilia A ahead of U.S. and EU regulatory filings. 5️⃣ Humanigen – Legal Challenges The DOJ indicted Humanigen’s former CEO and associates for insider trading and securities fraud—an important reminder of corporate accountability. 6️⃣ WuXi AppTec – Strategic Shift WuXi sold its cell and gene therapy business for $1.5 billion, reflecting strategic realignment in its service offerings. These milestones highlight the industry's relentless focus on innovation, patient care, and strategic growth. Which of these updates caught your attention? Let’s discuss! #PharmaInnovation #Biotech #GeneTherapy #HealthcareLeadership #ClinicalAdvancements #Citeline #PhaseIII #Pfizer #Sotyktu #Novo #Axsome #Sangamo #BMS

𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀 𝘄𝗶𝘁𝗵 𝗛𝗮𝘆𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝘁𝗼 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗹𝗼𝗻𝗴 𝗻𝗼𝗻𝗰𝗼𝗱𝗶𝗻𝗴 𝗥𝗡𝗔-𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗱𝗿𝘂𝗴 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀 𝗳𝗼𝗿 𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗖𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗢𝗯𝗲𝘀𝗶𝘁𝘆. Eli Lilly is partnering with Haya Therapeutics to discover new drug targets for chronic metabolic conditions and obesity. Founded in 2017, Haya has homed in on long noncoding RNAs (lncRNAs) as potential targets to treat diseases. These RNA molecules are not translated into proteins but, rather, interact with and regulate biological processes. Haya’s innovative platform focuses on identifying tissue- and disease-specific lncRNAs to develop RNA-targeting therapies. #obesity #metabolism #metabolicdisease #therapy #RNA #innovation #biotech #pharmaceuticalcompany #medicine

The role of CDMOs is evolving, driven by market opportunities and the demand for breakthrough therapies such as cell and gene therapies, mRNA treatments, and innovative vaccines. These advancements require innovative manufacturing capabilities, pushing CDMOs to lead in this landscape.

Meet the Early Strategic Advice team!   In today's rapidly evolving pharmaceutical landscape, prioritising the development of innovative medicines is critical. From small molecules to groundbreaking gene therapies, our team understands the critical role of early strategic advice in ensuring the success of these life-changing products.   Why is early engagement so vital? Because it lays the foundation for success by aligning regulatory and reimbursement strategies, and ensuring market access considerations are factored into early development plans - ultimately paving the way for patient access.   Led by Jo Wallis and Brad Groves, the team work across departments to provide you with the right strategic advice at the right point in your launch sequence.   Engage with our team early to optimise your clinical research and set the stage for successful HTA and reimbursement processes. Let's collaborate to bring your innovative therapies to patients who need them most, in the most efficient way. Connect with us now: https://lnkd.in/e6eHeZ3y   #Pharmaceuticals #Innovation #EarlyStrategicAdvice

🌱 Biopharmaceuticals: The Future of Medicine is Biotech! 🧬 The world of biopharmaceuticals is revolutionizing the way we treat diseases by developing drugs from biological sources such as proteins, nucleic acids, and even living cells. Here’s why biopharma is shaping the future of healthcare: 1. Targeted Treatments: Unlike traditional drugs, biopharmaceuticals can be designed to target specific molecular pathways in the body, offering more precise and effective treatments for conditions like cancer, autoimmune diseases, and rare genetic disorders. 2. Innovative Therapies: From monoclonal antibodies to gene therapies, biopharmaceuticals are opening new doors in personalized medicine, allowing treatments to be tailored to individual patient needs. 3. Reduced Side Effects: Because of their specificity, many biopharma products offer treatments with fewer side effects, improving the overall quality of patient care. 4. COVID-19 and mRNA Vaccines: The rapid development of mRNA vaccines during the COVID-19 pandemic is a clear example of how biopharmaceuticals can respond to global health crises with unprecedented speed and effectiveness. As biopharmaceuticals continue to evolve, they are playing a crucial role in developing next-generation treatments that are smarter, safer, and more personalized. Curious about how biotechnology is shaping the pharmaceutical industry? Let’s explore this exciting field together! 🌍 #Biopharmaceuticals #BiotechRevolution #GeneTherapy #MonoclonalAntibodies #PersonalizedMedicine #FutureOfHealthcare #PharmaInnovation #NextGenMedicine

Biologics Market size was valued at US$ 392.95 Bn. in 2023 and the total revenue is expected to grow at 9.1 % through 2024 to 2030, reaching nearly US$ 722.96 Bn. Click here for free sample + related graphs of the report: https://lnkd.in/d6jt3XQD The Biologics market is rapidly expanding, driven by advancements in biotechnology and an increasing focus on personalized medicine. Biologics, including monoclonal antibodies, vaccines, and gene therapies, offer targeted treatments for various chronic diseases, significantly improving patient outcomes. As the demand for innovative and effective therapies grows, the Biologics market is poised for continued growth, attracting substantial investment and driving breakthroughs in healthcare. #Biologics #Biotechnology #HealthcareInnovation #PersonalizedMedicine #Pharmaceuticals #GeneTherapy

𝐀𝐜𝐮𝐭𝐞 𝐈𝐧𝐭𝐞𝐫𝐦𝐢𝐭𝐭𝐞𝐧𝐭 𝐏𝐨𝐫𝐩𝐡𝐲𝐫𝐢𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰 The Acute Intermittent Porphyria (AIP) Therapeutics Market is witnessing growth due to increasing awareness about rare genetic disorders and advancements in precision medicine. The demand for targeted therapies, including gene therapies and RNA-based treatments, is rising. Government initiatives, improved diagnostic techniques, and enhanced patient support programs drive the adoption of innovative treatments, offering improved outcomes for AIP patients globally. 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨@https://lnkd.in/e8AkT6pR 𝐓𝐨𝐩 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Alnylam Pharmaceuticals Recordati Rare Diseases Pfizer. CLINUVEL PHARMACEUTICALS LTD Gilead Sciences TakedaPharmaceutical Nordics AB ROCHE LEON HOLDINGS AG Sanofi Vertex Pharmaceuticals Alexion Pharmaceuticals, Inc. Novartis Amgen. Johnson & Johnson Eli Lilly and Company Bayer Consumer Care AG Merck Group. Biogen CSL Behring B.V. AstraZeneca GSK (GSK) Thermo Fisher Scientific BioMarin Pharmaceutical Inc. Intellia Therapeutics, Inc. CRISPR Therapeutics Horizon Ipsen Ascendis Pharma Orphalan Silence Therapeutics plc #RareDiseases #PorphyriaTreatment #PrecisionMedicine #GeneticTherapies #InnovativeHealthcare

𝐀𝐧𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞𝐝 𝐔𝐒 𝐝𝐫𝐮𝐠 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 𝐚𝐧𝐝 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐢𝐧 2024 Novel drug approvals by the US FDA rose in 2023, reaching a record high of 71. Biologics accounted for just less than half, including the first CRISPR-Cas9–edited cell therapy, as well as gene therapies and bispecific antibodies. Among small molecules, four new oligonucleotide-based treatments were approved. More than half of all approvals targeted rare diseases. To increase patient access, the FDA approved more than 80 first generics and five biosimilars. The prognosis for approvals in 2024 looks healthy — based on Prescription Drug User Fee Act (PDUFA) dates — with as many as 59 drugs already showing potential to receive acceptance. A few expected approvals creating excitement include Moderna’s mRNA-based RSV vaccine, Eli Lilly’s Alzheimer’s drug (Donanemab) and BMS’s schizophrenia therapy (KarXT). Other anticipated approvals include Madrigal Pharmaceuticals’ resmetirom, Merck’s Sotatercept, Datopotamab from AstraZeneca and Daiichi Sankyo, BridgeBio Pharma’s Acoramidis, ImmunityBio’s Anktiva, Verona Pharma’s Ensifentrine and Iovance Biotherapeutics’ Lifileucel. 𝐘𝐨𝐮 𝐜𝐚𝐧 𝐩𝐥𝐚𝐜𝐞 𝐚𝐧 𝐨𝐫𝐝𝐞𝐫 𝐨𝐫 𝐚𝐬𝐤 𝐚𝐧𝐲 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬, 𝐩𝐥𝐞𝐚𝐬𝐞 𝐟𝐞𝐞𝐥 𝐟𝐫𝐞𝐞 𝐭𝐨 𝐜𝐨𝐧𝐭𝐚𝐜𝐭 𝐚𝐭 𝐬𝐚𝐥𝐞𝐬@𝐩𝐫𝐞𝐜𝐞𝐝𝐞𝐧𝐜𝐞𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡.𝐜𝐨𝐦 | +1 804 441 9344 #rehab #psychedelic #medical #pharmacist #high #pharmacology #rap #harmreduction #anxiety #follow #cocaine #doctor #drugmemes #addictionrecovery #adiksinarkoba #saynotodrugs #healthcare #addict #sober #pills #funny #addictivesubstance #weedmemes #grunge #withdrawalsymptom #covid #money #dialogue #mdma #drugabuseawareness

We're thrilled to announce Dr. Ananda Gopu PERUMAL, (Ph.D), Managing Director & R&D Head, Cell and gene therapy- CAR T, LYSINE BIOTECH PRIVATE LIMITED as our Esteemed Speaker for the 4th Edition of the India Biopharma Leaders Conclave, hosted by BlueTech Media™. Together, we're set to embark on a journey to explore "New Horizons in Biopharma, Biosimilars, & Biologics"! 🚀 . Date: 13th & 14th June, 2024, Hyderabad To Register for the event click https://lnkd.in/d2T9iruW . This year's theme promises a deep dive into the latest advancements shaping the biopharmaceutical landscape, with a spotlight on the exciting realms of biosimilars and biologics. With renowned speakers and eminent leaders from around the globe, this event is set to be a beacon of knowledge and innovation. . Why Attend: 🔍 Gain valuable insights into industry evolution, regulatory changes, and compliance challenges. 🤝 Expand your professional network by connecting with industry peers and potential collaborators. 💡 Discover cutting-edge products, services, and technologies driving biopharma innovation. 🔄 Engage in meaningful discussions to shape the future trajectory of the industry. 🔬 Explore challenges and opportunities, from regulatory hurdles to ethical considerations. . Event Highlights: 🎤 40+ Speakers 🤝 200+ Delegates 🤝 4+ Associations 📰 4+ Media Partners 🤝 15+ Partners . Key Topics Include: 🔬 The future and challenges of biosimilars 🔬 Success rates and challenges in biosimilar R&D 🔬 Quality, safety, and efficacy standards in biosimilars 🔬 Future of cell and gene therapy manufacturing 🔬 Emerging trends in quality assurance for biologics 🔬 Digitalized supply chains in biopharma 🔬 The crucial role of a digital backbone in the industry 🔬 Advances and barriers in CAR-T cell therapies Don't miss this opportunity to be at the forefront of biopharmaceutical innovation! . #Bluetechmedia #IndiaBiopharmaLeadersConclave #pharmaevents #pharmaceutical #Corporate #PharmaEvents #PharmaConferences #PharmaConclave #PharmaLeaders #BlueTechMedia #BiopharmaLeaders #Innovation #Biosimilars #Biologics #IndustryInsights